Orion Corporation

Orion-yhtyma Oy

Timo Lotta

Martti Ovaska

Jukka Vidgren

Jarmo J Pystynen

Marjo Yliperttula-Ikonen

Piero Pollesello

Juha Kaivola

Carola Tilgmann

Jukka Tenhunen

Aino K Pippuri

Inge-Britt Y Linden

Pentti Pohto

Anne M Luiro

Reijo B&auml;ckstr&ouml;m

Kari L&ouml;nnberg

Reijo Bäckström

P&auml;ivi Aho

Anita Koponen

Jyrki Taskinen

Compounds of formula I'wherein the two &#x2014;OH substituents in the phenyl moiety are in a position ortho to one another and Rin a position ortho to one of the hydroxy groups; and X, Rto Rare as defined in disclosure. The compounds exhibit COMT enzyme inhibiting activity, so are useful as COMT inhibitors.

Coumarin derivatives with COMT inhibiting activity

Compounds of formula (I'), wherein A, Rto Rand t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.

Derivatives of naphthalene with COMT inhibiting activity

This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, physicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of the active site of phospholamban.

Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors)

This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, phsicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of phospholamban.

Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)

The invention relates to the compounds of formula I:

Substituted &bgr; diketones and their use

Catechol derivatives

Growing community of inventors

Vantaa, Finland

Timo Lotta